Epoetin Alfa

Breastfeeding
  • TRADE NAMES: Binocrit; Epogen (Amgen); Epoxitin; Eprex (Janssen-Cilag); Erypo; Procrit (Ortho)
  • INDICATIONS: Anemia
  • SYNONYM: erythropoietin; EPO
  • CLASS: Erythropoiesis-stimulating agent (ESA), Erythropoietin
  • HALF-LIFE: 4–13 hours (in patients with chronic renal failure)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: C

ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

See full prescribing information for complete boxed warning.

Our database has 50 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 06/23/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top